See more : Signal Gold Inc. (SGNLF) Income Statement Analysis – Financial Results
Complete financial analysis of Chimeric Therapeutics Limited (CHMMF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Chimeric Therapeutics Limited, a leading company in the Biotechnology industry within the Healthcare sector.
- JcbNext Berhad (0058.KL) Income Statement Analysis – Financial Results
- Ivanhoe Electric Inc. (IE) Income Statement Analysis – Financial Results
- Wuhan Youji Holdings Ltd (2881.HK) Income Statement Analysis – Financial Results
- Nova Vision Acquisition Corporation (NOVVW) Income Statement Analysis – Financial Results
- Fagron NV (ARSUF) Income Statement Analysis – Financial Results
Chimeric Therapeutics Limited (CHMMF)
About Chimeric Therapeutics Limited
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies in oncology in Australia. The company develops CHM 0201 (core NK platform) that is in phase I clinical trial for treating solid tumors and hematological malignancies; and CHM 1101 (CLTX CAR T), which is in phase I clinical trial for treating patients with MMP2+ recurrent or progressive glioblastoma. It is also developing CHM 0301 for blood cancers; CHM 1301 (CLTX CAR NK) and CHM 2301 (CDH17 CAR NK) for solid tumors; CHM 1101 (CLTX CAR T) for melanoma, colorectal, and prostate; and CHM 2101 (CDH17 CAR T) for neuroendocrine, colorectal, pancreatic, and gastric. The company was incorporated in 2020 and is based in Carlton, Australia.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 4.51M | 2.62M | 0.00 | 0.00 |
| Cost of Revenue | 3.92K | 965.35K | 949.76K | 846.96K | 0.00 |
| Gross Profit | -3.92K | 3.54M | 1.67M | -846.96K | 0.00 |
| Gross Profit Ratio | 0.00% | 78.58% | 63.71% | 0.00% | 0.00% |
| Research & Development | 11.15M | 13.47M | 5.17M | 3.78M | 0.00 |
| General & Administrative | 0.00 | 11.92M | 9.14M | 6.02M | 151.82K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 148.69K | 1.80K |
| SG&A | 9.57M | 11.92M | 9.14M | 6.17M | 64.01K |
| Other Expenses | 0.00 | 4.83M | 2.08M | -263.79K | 0.00 |
| Operating Expenses | 20.72M | 29.49M | 17.19M | 15.69M | 64.01K |
| Cost & Expenses | 20.72M | 29.49M | 17.19M | 15.69M | 64.01K |
| Interest Income | 121.32K | 27.57K | 12.98K | 2.65K | 0.00 |
| Interest Expense | 331.81K | 773.85K | 640.13K | 5.88K | 0.00 |
| Depreciation & Amortization | 3.92K | 965.35K | 949.76K | 846.96K | 153.62K |
| EBITDA | -20.72M | -23.67M | -14.14M | -14.26M | -64.01K |
| EBITDA Ratio | 0.00% | -525.24% | -540.39% | 0.00% | 0.00% |
| Operating Income | -20.72M | -24.63M | -15.09M | -15.11M | -64.01K |
| Operating Income Ratio | 0.00% | -546.67% | -576.68% | 0.00% | 0.00% |
| Total Other Income/Expenses | -514.84K | -426.09K | -1.16M | -267.02K | 3.00 |
| Income Before Tax | -21.23M | -25.41M | -15.73M | -15.11M | -64.01K |
| Income Before Tax Ratio | 0.00% | -563.89% | -601.22% | 0.00% | 0.00% |
| Income Tax Expense | -8.70M | 92.82K | 163.72K | -257.91K | -153.62K |
| Net Income | -12.53M | -25.50M | -15.90M | -15.11M | -64.01K |
| Net Income Ratio | 0.00% | -565.95% | -607.48% | 0.00% | 0.00% |
| EPS | -0.02 | -0.06 | -0.04 | -0.05 | 0.00 |
| EPS Diluted | -0.02 | -0.06 | -0.04 | -0.05 | 0.00 |
| Weighted Avg Shares Out | 695.64M | 433.24M | 359.93M | 325.51M | 342.92M |
| Weighted Avg Shares Out (Dil) | 695.64M | 433.24M | 359.93M | 325.50M | 342.92M |
Source: https://incomestatements.info
Category: Stock Reports